Trial Now Recruiting: Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis (NCT04592640)
WHY IT MATTERS
Calciphylaxis has very few treatment options and high mortality rates — this trial offers patients with chronic kidney disease a chance to access an experimental stem cell therapy that could reduce tissue damage and improve survival.
Researchers are testing a new treatment for calciphylaxis, a serious condition where calcium builds up in blood vessels and skin tissue, causing painful sores. The treatment uses special cells from amniotic fluid (the fluid around a baby during pregnancy) to see if they can help heal the damage. This is an early-stage trial with a small group of 9 patients to check if the treatment is safe and works.
NCT ID: NCT04592640 Status: RECRUITING Conditions: Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy, Treatment, Safety, Efficacy Phase: EARLY_PHASE1 Enrollment: 9 Sponsor: The First Affiliated Hospital with Nanjing Medical University Summary: Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
YOU CAN ACT ON THIS
If you have calciphylaxis or calcific uremic arteriolopathy and chronic kidney disease, contact The First Affiliated Hospital with Nanjing Medical University or check clinicaltrials.gov (NCT04592640) to see if you meet enrollment criteria.